Literature DB >> 2473320

Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells.

M R Boarder1, D B Marriott.   

Abstract

Addition of endothelin-1 (ET-1) to primary cultures of bovine adrenal chromaffin cells causes a significant enhancement of norepinephrine and epinephrine efflux, with an EC50 of about 1 nM. A maximally effective concentration of endothelin (10 nM) gives a transient increase in noradrenaline release within 5 min. The amounts of noradrenaline and adrenaline released by ET-1 was smaller than the release elicited by maximally effective concentrations of bradykinin or prostaglandin E2. These results raise the possibility that the vascular endothelium may stimulate release from chromaffin cells by production of ET-1.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473320     DOI: 10.1097/00005344-198900135-00066

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man.

Authors:  J R Cockcroft; J G Clarke; D J Webb
Journal:  Br J Clin Pharmacol       Date:  1991-05       Impact factor: 4.335

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Endothelin in congestive heart failure.

Authors:  M P Love; J J McMurray
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

6.  Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans.

Authors:  M C Verhaar; A Y Grahn; A W Van Weerdt; M L Honing; P J Morrison; Y P Yang; R J Padley; T J Rabelink
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 7.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

8.  Endothelin as an autocrine factor in the regulation of parathyroid cells.

Authors:  Y Fujii; J E Moreira; C Orlando; M Maggi; G D Aurbach; M L Brandi; K Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

9.  Alterations in circulating vasoactive substances in the critically ill--a comparison between survivors and non-survivors.

Authors:  J Boldt; T Menges; D Kuhn; C Diridis; G Hempelmann
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

10.  Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells.

Authors:  M Takahashi; K Fukuda; K Shimada; K Barnes; A J Turner; M Ikeda; H Koike; Y Yamamoto; K Tanzawa
Journal:  Biochem J       Date:  1995-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.